www.standoutstocks.com: Stocks That Stand Out For Nov. 9th, 2009 Are ZAGG, JAZZ, NNVC, KDKN

www.StandoutStocks.com: Stocks That Standout For Nov. 9th, 2009 are ZAGG Inc. (OTCBB: ZAGG), Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ), NanoViricides, Inc. (OTCBB: NNVC), Kodiak Energy, Inc. (TSX VENTURE: KDK) (OTCBB: KDKN)

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com __________________________________________________

ZAGG Opens First Inline Retail Mall Store

New Mall Location to Carry Full Range of ZAGG Merchandise

SALT LAKE CITY, Nov 09, 2009 -- ZAGG Inc. (OTCBB: ZAGG), a leading producer of electronics accessories for protecting and enhancing the mobile experience, including the popular patented invisibleSHIELD(TM) and ZAGGaudio(TM) brands, announces the opening of their first inline store.

Located in the University Mall in Orem, Utah, the inline store is an expansion of ZAGG's successful invisibleSHIELD mall cart in the same mall. Similar to the majority of ZAGG's mall carts, the first inline retail mall store is launching through a licensed vendor. The grand opening is today, November 9, 2009.

"We have a great opportunity to expand our retail presence with this first ZAGG inline store," said Derek Smith, VP of Sales for ZAGG. "The invisibleSHIELD mall cart in the University Mall is very successful, and we needed to make this move to accommodate for more needed space due to our increasing product lines and customer acceptance of the mall cart and kiosk program." ZAGG's mall cart program was founded in 2006 with a single location, and has since expanded to over 80 carts across the United States. The mall cart model provides a retail setting in a convenient location where gadget lovers can purchase the invisibleSHIELD for their electronics and have it installed on site. The expanded inline model will provide retail space for the full line of ZAGG accessories, including ZAGGaudio's ZAGGbuds, the soon to be released ZAGGsparq, ZAGGfoam, and the popular ZAGGskins. In addition, the inline store will be a center for demonstrating and offering the highly anticipated ZAGGbox in early spring.

"Our goal for 2009 was to achieve 80 carts by year end, and we successfully reached that goal well ahead of schedule," said Smith. "We entered the year with 37 carts in 13 states, and we now have 81 carts in 21 states. This 218% growth in locations for the year introduces the invisibleSHIELD -- and now other unique ZAGG products -- to thousands and thousands of potential new customers every day." "Our mall cart program works very well, and the inline store model is the natural evolution for our licensee partners to work toward," said Robert G. Pedersen II, President and CEO of ZAGG. "I always dreamed of having our own ZAGG store chain, but it has not been until now that we are ready for it. Opening our first inline store is the start and will help us reach more customers and add to ZAGG's value as a tenant in leading malls across the country. As a company, having licensees open the stores, like our carts, is not a corporate capital expense but rather a revenue driver and brand builder. Our licensees will also benefit greatly. It is a real win for everyone." For more information about ZAGG or their product lines, please visit www.ZAGG.com.

About ZAGG Inc.: ZAGG is dedicated to protecting and enhancing the mobile experience. ZAGG designs, manufactures, and distributes protective clear coverings and accessories for consumer electronic and hand-held devices, worldwide under the brand names invisibleSHIELD(TM) and ZAGGaudio(TM). ZAGG has also introduced beta testing of AppSpace.com, an online destination for the fast-growing mobile app market, combined with the networking power of social media. The invisibleSHIELD is a protective, high-tech patented film covering, designed for iPods, laptops, cell phones, digital cameras, PDAs, watch faces, GPS systems, gaming devices, and other items. The patent-pending invisibleSHIELD application of clear protective film covering a device is the first scratch protection solution of its kind on the market, and has sold millions of units. Currently, ZAGG offers over 4,000 precision pre-cut designs with a lifetime replacement warranty through ZAGG.com, major retailers like Best Buy and RadioShack, resellers, college bookstores, Mac stores, mall kiosks, and other online retailers. The company continues to increase its product lines to offer additional electronic accessories and services to its tech-savvy customer base, including upcoming technologies like ZAGGbox, to be introduced at CES 2010, and HzO, a breakthrough gadget waterproofing technology. For more product or investor information please visit the company's web site at www.ZAGG.com.

Safe Harbor Statement: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in filings made by the company with the Securities and Exchange Commission.

Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results

---Achieved Record Quarterly Net Product Sales of $30 Million--- Raising Revenue Guidance for 2009

PALO ALTO, Calif., Nov 05, 2009 -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2009.

Total revenues for the third quarter of 2009 were $30.8 million, compared to $17.7 million for the quarter ended September 30, 2008. XYREM(R) (sodium oxybate) oral solution net sales for the third quarter of 2009 were $25.0 million, compared to $14.2 million for the third quarter of 2008, and represented a 12% sequential increase over net sales of $22.4 million for the second quarter of 2009. Net sales of once-daily LUVOX CR(R) (fluvoxamine maleate) extended-release capsules were $5.0 million for the third quarter of 2009, compared to $2.0 million for the third quarter 2008, and represented a 20% sequential increase over net sales of $4.1 million for the second quarter of 2009. Total revenues for the third quarter of 2009 also included $0.8 million in royalties and contract revenue.

"Our sales team delivered another solid quarter for us with record numbers of XYREM and LUVOX CR prescriptions and net sales" said Bob Myers, President of Jazz Pharmaceuticals.

Research and development expenses for the third quarter of 2009 were $7.6 million, compared to $12.1 million for the third quarter of 2008. This reduction from $11.2 million for the second quarter of 2009 was primarily due to the completion of the second Phase III pivotal clinical efficacy trial for JZP-6, sodium oxybate for the treatment of fibromyalgia, in June of 2009. Jazz Pharmaceuticals expects to submit a New Drug Application for JZP-6 by the end of 2009.

Jazz Pharmaceuticals' net loss for the third quarter of 2009 was $1.7 million, compared to a net loss of $28.8 million for the third quarter of 2008.

Jazz Pharmaceuticals is increasing its full-year 2009 guidance for XYREM and LUVOX CR net sales, and tightening its guidance for R&D expenses:

Prior Guidance Updated Guidance

-------------- ----------------

- Total revenues $112 - 122 million $122 - 127 million

- XYREM net sales $85 - 90 million $92 - 95 million

- LUVOX CR net sales $15 - 18 million $17 - 19 million

- Contract revenues and royalties $12 - 14 million ~ $13 million

- R&D expenses $35 - 45 million $36 - 40 million

"We have made impressive strides in transforming our business in 2009," said Bruce Cozadd, Chairman and Chief Executive Officer of Jazz Pharmaceuticals. "In the first nine months of 2008, we had net product sales of $45.8 million and an operating loss of $118.6 million. In the first nine months of 2009, we achieved net product sales of $77.8 million and operating income of $4.5 million. Our commercial business continues to grow and we look forward to submitting our NDA for JZP-6 next month." Jazz Pharmaceuticals will host an investor conference call and live audio webcast to give a company update, as well as to discuss financial results and guidance, today (November 5, 2009) commencing at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The live webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.JazzPharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing 1-866-825-1692 in the U.S., or 1-617-213-8059 outside the U.S., and entering passcode 25459996.

An archived version of the webcast will be available through November 19, 2009. This replay can be accessed from the Investors section of the Jazz Pharmaceuticals' website at www.JazzPharmaceuticals.com, or by calling 888-286-8010 in the U.S., or 617-801-6888 outside the U.S., and entering passcode 83883148.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' ability to appropriately grow net product sales, the expected New Drug Application submission date for the JZP-6 product candidate, and Jazz Pharmaceuticals' full-year 2009 guidance. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' ability to increase sales of XYREM and LUVOX CR; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the uncertain and time-consuming regulatory approval process for JZP-6; Jazz Pharmaceuticals' cash flow estimates; Jazz Pharmaceuticals' ability to use its net operating losses to offset taxes; competition; the holders of Jazz Pharmaceuticals' senior secured notes attempting to accelerate the notes as a result of past events of default or Jazz Pharmaceuticals' inability to comply with the terms of the agreement governing the senior secured notes on an ongoing basis; Jazz Pharmaceuticals' future financial performance and financial position; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on August 14, 2009. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

NanoViricides, Inc. to Present Anti-Influenza Drug Candidate FluCide(TM) Studies at the Influenza Congress 2009

WEST HAVEN, Conn., Nov 09, 2009 -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company's CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the "Evolving Role of Anti-Virals" in influenza treatment.

Dr. Seymour will review the Company's recent in vivo studies against influenza. The success of these studies has led the Company to consolidate its anti-influenza drug programs into a single, pan-influenza drug, "FluCide(TM)". This single drug is expected to be highly effective against all forms of influenza A, including the recent "swine flu" 2009/CA/H1N1 strain, seasonal flu strains, as well as H5N1 bird flu strains feared to be capable of creating a devastating pandemic, and other highly pathogenic strains on the horizon.

A "pan-influenza" drug is widely sought in order to enable treating infections from novel influenza viruses. It is well known that pandemics can be caused by novel strains of influenza. Fortunately the current "swine flu" H1N1/2009 pandemic is now believed to cause fatality rates comparable to seasonal influenzas. However, influenza viruses are known to change rapidly. New influenza viruses are often generated by mixing of genetic material from existing influenza viruses, known as "reassortments". Such changes can lead to a novel virus that is capable of causing a wide-spread pandemic accompanied by a high fatality rate. In addition, mutations are known to have led to influenza strains resistant to existing anti-influenza drugs. The Company believes that FluCide is designed to minimize the possibility of resistant mutations.

All of the Company's anti-influenza studies to date have been conducted by independent external investigators.

Dr. Seymour will join other industry panelists in the "Evolving Role of Anti-Virals" session to discuss drug resistance, drug efficacy and clinical development of anti-viral treatments for influenza. The panelists and participants include pharmaceutical and biotech decision makers and executives as well as government and regulatory agency representatives from a number of countries. This conference is designed to bring together key stakeholders from the pharmaceutical and biotech industries, as well as governmental science and regulatory segments to discuss appropriate responses to the evolving influenza pandemic, according to the organizers.

About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Kodiak Energy, Inc. and Subsidiary Cougar Energy, Inc. Appoints VP Finance and CFO

CALGARY, ALBERTA, Nov 05, 2009 -- Kodiak Energy, Inc. (TSX VENTURE: KDK) (OTCBB: KDKN) ("Kodiak" or the "Corporation") and its majority controlled private subsidiary, Cougar Energy, Inc. ("Cougar"), welcomes David (Dave) Wilson as Vice President, Finance of Kodiak and Chief Financial Officer of Cougar effective November 2, 2009. Additional information for Dave Wilson can be found at http://www.kodiakpetroleum.com/s/Management.asp.

Dave has over 20 years of professional accounting experience with various public and private oil and gas exploration companies, both domestically and internationally. He has expertise in accounting, securities and regulatory standards for publicly traded companies including U.S. GAAP and Canadian IFRS. Dave is also accomplished in various financing initiatives, related negotiations, and M&A transactions. His proven executive management skills in the capacities of Vice President, Finance and Chief Financial Officer were instrumental in successfully executing various strategic transactions. He obtained his Certified Management Accountant designation from the Alberta Society of Management Accountants.

"I am delighted in joining Kodiak and Cougar at this exciting time in the companies' growth," stated Dave Wilson. "I look forward to working with both executive management teams to create opportunities and implement financial and operational strategies to move the companies forward." "We are excited to add such a qualified and experienced member to our executive management teams", said Bill Tighe, President and CEO of Kodiak. "Dave's comprehensive level of industry, accounting and regulatory knowledge comes at a significant turning point for both Kodiak and Cougar." With the appointment of Dave Wilson as Vice President, Finance of Kodiak and Chief Financial Officer of Cougar, Bill Brimacombe remains Chief Financial Officer of Kodiak and has stepped down as Chief Financial Officer of Cougar.

About Cougar: Cougar Energy, Inc. is based in Calgary, Alberta Canada and a privately held subsidiary of parent company, Kodiak Energy, Inc. The focus is on the exploration and development of Canadian based onshore oil and gas properties. The current projects are Lucy in the Horn River Basin in northeast British Columbia and CREEnergy Joint Venture and area projects located in north central Alberta. Additional information on the "Lucy" and CREEnergy projects are available at http://www.cougarenergyinc.com.

About Kodiak: Kodiak Energy, Inc. is a Calgary, Alberta, Canada based publicly traded oil and gas exploration and development company focused on developing and exploring onshore oil, gas and CO2 properties within North America. Our main prospect is located in the northeast New Mexico. Through our private subsidiary, Cougar Energy, Inc., we are developing the projects of Lucy in the Horn River Basin in northeast British Columbia and CREEnergy Joint Venture and area projects located in north central Alberta. Additional information on Kodiak is at http://www.kodiakpetroleum.com.

Forward-looking Statements: This press release contains forward-looking statements. The words or phrases "would be," "will" "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," or similar expressions are intended to identify "forward-looking statements". The Corporation's business is subject to various other risks and uncertainties, which may be described in its corporate filings (www.sec.gov and www.sedar.com). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Corporation cautions readers not to place reliance on such statements. Kodiak undertakes no obligation to update or publicly revise forward looking statements or information unless so required by applicable securities laws.

About Standoutstocks.com www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx

CONTACT: Jason A. Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: Jason@Newmediaadvisorsllc.com e-mail: info@standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: accounting, alberta, biotechnology, british columbia, broker, business, calgary, california, canada, cart, ceo, clinical, college, commercial, conference, congress, connecticut, consumer, contract, corporate, dealer, drugs, electronics, email, e-mail, energy, executive, expansion, exploration, film, finance, financial results, gasoline, government, hiv, infection, investment, investment opinion, jazz, joint venture, manufacturer, market, media, medical, nasdaq, new mexico, north america, oil, oil and gas, online, otc, pharmaceuticals, president, prices, products, rates, research and development, retail, revenue, sales, schedule, science, securities, software, standards, subscription, swine, taxes, technology, trial, utah, washington dc, web